Adjunction of inhaled amikacin to intravenous standard-of-care antibiotics do not modified short term prognosis of Ventilator Associated Pneumonia due to Gram-negative bacilli.

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.

  • Niederman MS. et al.
  • Rédigé par : Dr Olivier Leroy
The ESCMID recommendations published in 2017 (ATB-VAC 31/5/2017) are clear: the use of inhaled antibiotics in ICU should be prohibited. The Infectious Diseases Society of America and American Thoracic Society (IDSA/ATS) guidelines, suggest that VAP due to Gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins should be treated with both inhaled and intravenous antibiot...
Ce contenu est à destination des professionnels de santé. Merci de vous identifier.
This content is intended for healthcare professionals. Thank you for identifying yourself.

Déjà inscrit / Already registered ?

Créer un compte / Create an account

Créer un compte ne prend que quelques minutes et vous permettra d'accèder à l'ensemble des contenus du site.
Creating an account takes only instant and will allow you to access all the content of the website.